ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc has announced significant findings from studies presented at the 5th Advances in Circulating Tumour Cells (ACTC) conference. The research utilizing ANGLE's Parsortix system identified novel circulating tumor cell (CTC) biomarkers in ovarian and lung cancer, indicating potential for personalized treatment. A Phase II trial showed that gene analysis of CTCs could predict patient responses, with 85% survival for responders at 120 days. Additional studies highlighted the presence of p53 protein in small cell lung cancer and identified crucial markers for non-small cell lung cancer prognosis.

ANGLE plc has announced that a study from the Health Research Institute of Santiago demonstrates the effectiveness of the Parsortix system in assessing PD-L1 status in circulating tumor cells (CTCs) for non-small cell lung cancer (NSCLC) patients. This liquid biopsy method, which is safer than traditional tissue biopsies, offers a promising approach to monitor treatment responses. ANGLE is further developing a PD-L1 assay for use in cancer drug trials and aims to collaborate with leading cancer centers for validation. The study highlights the need for improved patient selection due to low response rates to current therapies.

ANGLE plc has announced significant advancements with its Parsortix system in analyzing gene expression in metastatic prostate cancer (mPCa) patients. A study by the Medical University of Innsbruck revealed that Parsortix successfully isolated circulating tumor cells (CTCs) in 80% of patients, offering a viable alternative when tissue biopsies are not possible. Longitudinal monitoring indicated a drop in CTCs correlating with positive drug responses, further underscoring its potential for pharma services. With approximately 3.2 million U.S. men living with prostate cancer, these findings may guide personalized treatment decisions.

ANGLE plc (OTCQX:ANPCY) will release its interim results for the six months ending June 30, 2021, on September 30, 2021. A virtual meeting for analysts starts at 10:00 AM BST the same day. Registration is required to attend the webcast, which serves as a watch-only platform with Q&A reserved for analysts. ANGLE is a leader in liquid biopsy, known for its Parsortix technology enabling non-invasive cancer cell analysis. The company aims for FDA clearance for CTC harvesting, which could elevate its market position significantly.

ANGLE plc has announced the allotment of 500,000 new ordinary shares following the exercise of share options by Finance Director Ian Griffiths at £0.2575 each. This transaction boosts Griffiths' holdings to 1,203,832 shares, approximately 0.5% of issued share capital. Application for the shares' trading admission will be made, with an expected effective date of August 27, 2021. Post-admission, the total number of ordinary shares will be 234,848,051, which shareholders can use to calculate their interest changes under FCA regulations.

ANGLE plc announced a study from the Institute of Oncology, Slovenia that demonstrates the superior performance of its Parsortix system in harvesting circulating tumor cells (CTCs) from metastatic breast cancer patients. The study highlighted that 64% of patients yielded CTCs using Parsortix compared to 57% with an antibody-based system. The Parsortix method also preserved the morphology of 99% of the isolated cells, enhancing quality and analysis potential. This positions Parsortix for routine integration in clinical laboratories, addressing the need for non-invasive biopsy options for patients.

ANGLE plc (OTCQX:ANPCY) announced the issuance of 140,000 new ordinary shares following the exercise of employee options. The new shares will rank equally with existing shares and are set to be admitted to trading on AIM on August 12, 2021. Post-admission, the total number of ordinary shares in issue will be 234,348,051. This move is part of the company's ongoing strategy to enhance its capital structure and support its liquid biopsy technologies, which have demonstrated promising clinical results in cancer diagnostics.

ANGLE plc (OTCQX:ANPCY) has issued 26,667 new ordinary shares following the exercise of employee options, increasing the total shares to 234,208,051. The new shares will begin trading on the London Stock Exchange on 9 August 2021. ANGLE is renowned for its liquid biopsy technology, the Parsortix system, which allows non-invasive cancer cell analysis and has shown significant accuracy in clinical studies, particularly for ovarian cancer. The company is pursuing FDA clearance for its system, aiming to enhance its market position in oncology diagnostics.

ANGLE plc has secured a pharma services contract for developing two custom CTC assays targeting DNA damage repair biomarkers. The contract, valued at approximately US$ 400,000, involves developing assays for four challenging cancers: triple negative breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer. The initial phase will provide significant revenue and, if successful, will lead to further clinical trials planned for H2 2022. The assays will enhance ANGLE's service offerings to pharma clients by enabling targeted analysis on circulating tumor cells.